News– category –
-
TNAX Biopharma Corporation and IMIDomics Inc. have entered into a license agreement
-
The University of Tsukuba and TNAX team discovered a target that ameliorates post-ischemic stroke neurological damages
-
University of Tsukuba and TNAX Biopharma Corporation identified an antibody and findings were published in Proc Natl Acad Sci USA
-
Our article was on the on line magazine “Nikkei Bitotech”.
-
TNAX Biopharma was authorized as a startup originated from University of Tsukuba
1